160 related articles for article (PubMed ID: 31721608)
1. New avenues in pancreatic cancer: exploiting microRNAs as predictive biomarkers and new approaches to target aberrant metabolism.
Capula M; Mantini G; Funel N; Giovannetti E
Expert Rev Clin Pharmacol; 2019 Dec; 12(12):1081-1090. PubMed ID: 31721608
[No Abstract] [Full Text] [Related]
2. MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.
Daoud AZ; Mulholland EJ; Cole G; McCarthy HO
BMC Cancer; 2019 Nov; 19(1):1130. PubMed ID: 31752758
[TBL] [Abstract][Full Text] [Related]
3. The Role of MicroRNAs in Resistance to Current Pancreatic Cancer Treatment: Translational Studies and Basic Protocols for Extraction and PCR Analysis.
Garajová I; Le Large TY; Giovannetti E; Kazemier G; Biasco G; Peters GJ
Methods Mol Biol; 2016; 1395():163-87. PubMed ID: 26910074
[TBL] [Abstract][Full Text] [Related]
4. Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.
Khan MA; Zubair H; Srivastava SK; Singh S; Singh AP
Adv Exp Med Biol; 2015; 889():71-87. PubMed ID: 26658997
[TBL] [Abstract][Full Text] [Related]
5. The prognostic and therapeutic application of microRNAs in breast cancer: Tissue and circulating microRNAs.
Bahrami A; Aledavood A; Anvari K; Hassanian SM; Maftouh M; Yaghobzade A; Salarzaee O; ShahidSales S; Avan A
J Cell Physiol; 2018 Feb; 233(2):774-786. PubMed ID: 28109133
[TBL] [Abstract][Full Text] [Related]
6. Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review).
Subramani R; Gangwani L; Nandy SB; Arumugam A; Chattopadhyay M; Lakshmanaswamy R
Int J Oncol; 2015 Oct; 47(4):1203-10. PubMed ID: 26314882
[TBL] [Abstract][Full Text] [Related]
7. Molecular subtypes of pancreatic cancer based on miRNA expression profiles have independent prognostic value.
Namkung J; Kwon W; Choi Y; Yi SG; Han S; Kang MJ; Kim SW; Park T; Jang JY
J Gastroenterol Hepatol; 2016 Jun; 31(6):1160-7. PubMed ID: 26644397
[TBL] [Abstract][Full Text] [Related]
8. The underlying mechanisms of non-coding RNAs in the chemoresistance of pancreatic cancer.
Xiong G; Feng M; Yang G; Zheng S; Song X; Cao Z; You L; Zheng L; Hu Y; Zhang T; Zhao Y
Cancer Lett; 2017 Jul; 397():94-102. PubMed ID: 28254409
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of new drugs for pancreatic cancer.
Sugarman R; Patel R; Sharma S; Plenker D; Tuveson D; Saif MW
Expert Opin Drug Metab Toxicol; 2019 Jul; 15(7):541-552. PubMed ID: 31241371
[No Abstract] [Full Text] [Related]
10. Pharmacogenetics of treatments for pancreatic cancer.
El Hassouni B; Li Petri G; Liu DSK; Cascioferro S; Parrino B; Hassan W; Diana P; Ali A; Frampton AE; Giovannetti E
Expert Opin Drug Metab Toxicol; 2019 Jun; 15(6):437-447. PubMed ID: 31100206
[No Abstract] [Full Text] [Related]
11. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer.
Caparello C; Meijer LL; Garajova I; Falcone A; Le Large TY; Funel N; Kazemier G; Peters GJ; Vasile E; Giovannetti E
World J Gastroenterol; 2016 Aug; 22(31):6987-7005. PubMed ID: 27610011
[TBL] [Abstract][Full Text] [Related]
12. MicroRNAs as biomarkers and perspectives in the therapy of pancreatic cancer.
Xia T; Chen XY; Zhang YN
Mol Cell Biochem; 2021 Dec; 476(12):4191-4203. PubMed ID: 34324119
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-196b is an independent prognostic biomarker in patients with pancreatic cancer.
Kanno S; Nosho K; Ishigami K; Yamamoto I; Koide H; Kurihara H; Mitsuhashi K; Shitani M; Motoya M; Sasaki S; Tanuma T; Maguchi H; Hasegawa T; Kimura Y; Takemasa I; Shinomura Y; Nakase H
Carcinogenesis; 2017 Apr; 38(4):425-431. PubMed ID: 28186267
[TBL] [Abstract][Full Text] [Related]
14. Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer.
Rachagani S; Macha MA; Heimann N; Seshacharyulu P; Haridas D; Chugh S; Batra SK
Adv Drug Deliv Rev; 2015 Jan; 81():16-33. PubMed ID: 25453266
[TBL] [Abstract][Full Text] [Related]
15. Current and future biomarkers for pancreatic adenocarcinoma.
Loosen SH; Neumann UP; Trautwein C; Roderburg C; Luedde T
Tumour Biol; 2017 Jun; 39(6):1010428317692231. PubMed ID: 28618958
[TBL] [Abstract][Full Text] [Related]
16. Downregulated miR-506 expression facilitates pancreatic cancer progression and chemoresistance via SPHK1/Akt/NF-κB signaling.
Li J; Wu H; Li W; Yin L; Guo S; Xu X; Ouyang Y; Zhao Z; Liu S; Tian Y; Tian Z; Ju J; Ni B; Wang H
Oncogene; 2016 Oct; 35(42):5501-5514. PubMed ID: 27065335
[TBL] [Abstract][Full Text] [Related]
17. The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.
Hawa Z; Haque I; Ghosh A; Banerjee S; Harris L; Banerjee SK
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240340
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer.
Pishvaian MJ; Brody JR
Oncology (Williston Park); 2017 Mar; 31(3):159-66, 168. PubMed ID: 28299752
[TBL] [Abstract][Full Text] [Related]
19. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
[TBL] [Abstract][Full Text] [Related]
20. Integrating MicroRNA Expression Profiling Studies to Systematically Evaluate the Diagnostic Value of MicroRNAs in Pancreatic Cancer and Validate Their Prognostic Significance with the Cancer Genome Atlas Data.
Zhang Z; Pan B; Lv S; Ji Z; Wu Q; Lang R; He Q; Zhao X
Cell Physiol Biochem; 2018; 49(2):678-695. PubMed ID: 30165365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
